

Evaluation of a sunscreen product compared with established reference products in outdoor conditions

Submission date 07/07/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 11/08/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 30/09/2022	Condition category Skin and Connective Tissue Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

The aim of this study is to provide evidence of how a new broad-spectrum sunscreen SPF50 performs in outdoor conditions of extreme solar exposure compared with established reference sunscreens established by the International Organization for Standardization in 2019 (ISO 24444: 2019).

Who can participate?

Caucasian healthy adult volunteers.

What does the study involve?

The study will take place in an outdoor facility in Mauritius between November 2021 and December 2021. Each participant will receive treatment with the broad-spectrum SPF50 sunscreen (investigational product) and 3 reference ISO products: P3 (SPF15), P5 (SPF30), and P8 (SPF50+). Each of the 4 products will be applied to one of 6 defined areas of the participants' backs, with the remaining 2 areas treated with no sunscreen. The products will all be applied at the same density.

The sunscreen-treated areas will be exposed to the sun for 2 or 3 hours (depending on their baseline skin color). The amount of Ultraviolet A (UVA) and Ultraviolet B (UVB) radiation that participants receive during this time will be measured. Participants' skin will be assessed after 24 hours and after 1 week.

What are the possible benefits and risks of participating?

This study was without direct benefit to the participant. There was a minimum risk predictable to subjects' health given that the composition of the test products only used known ingredients at safe concentrations. It was however considered that there was still a theoretical possibility of local skin reactions (such as allergic dermatitis or irritant dermatitis) and that sunburn on the test area could not be totally excluded given the high UV indexes. Subjects were instructed to contact the investigator site if any of those reactions occurred and they were followed up until the total resolution of the adverse event. In case of any adverse event after the study period, the subjects were requested to contact the investigator site to be examined by the

dermatologist investigator. The study investigator had to follow up on the evolution of the event and determine the relationship to the test product if applicable. The safety of the investigational product had been proved through previous studies as demonstrated in the safety declaration.

Where is the study run from?
ISDIN (Spain)

When is the study starting and how long is it expected to run for?
September 2021 to December 2021

Who is funding the study?
ISDIN (Spain)

Who is the main contact?
Mr Javier Bustos, javier.bustos@isdin.com

Contact information

Type(s)
Public

Contact name
Mr Javier Bustos

ORCID ID
<http://orcid.org/0000-0001-6892-4814>

Contact details
ISDIN
Provençals 33
08019 Barcelona
Spain
Barcelona
Spain
08019
+34 932 402 020
javier.bustos@isdin.com

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number
Nil known

Secondary identifying numbers

Study information

Scientific Title

Evaluation of sun protective effect of a sunscreen product under outdoor conditions compared to SPF15, SPF30 and SPF50+. A randomized, double blind, intra-individual, single center clinical study in healthy subjects

Study objectives

Efficacy of a broad-spectrum SPF 50 sunscreen in comparison with other reference products in outdoor conditions

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 11/10/2021, IBL Life Ltd Ethics Committee (4th Floor, IBL House, Caudan Waterfront, 11307, Port Louis, Mauritius; +230 203 2000; iblinfo@iblgroupp.com), ref: EC21-COS-067-1

Study design

Double-blinded, single-center, within-subject randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Prevention

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Sunburn

Interventions

On day 1, participants will be assessed using calorimetry to calculate Individual Typology Angle (ITA). Then the investigational product and reference products will be applied to the back of the subjects on randomized defined areas between the scapula and the waist (6 areas per subject). Each area was treated with a different sunscreen: either the investigational product (sunscreen SPF 50), the standard reference products from ISO 24444:2019: P3 (SPF15), P5 (SPF30), and P8 (SPF50+), or no sunscreen (2 areas with no sunscreen, as positive and negative control). Application of the investigational product, as well as standard reference products, on the treated area, was done according to the randomization list. The tested areas were defined as

healthy areas on the back. For safety reasons, the non-treated area was not blinded. Products were applied at 2 mg/cm².

The comparison will be performed under very high and extreme UV radiations conditions, in an outdoor conditions (at an outdoor facility in Mauritius between November 2021 and December 2021). The exposition time (2-3 h) of each subject corresponded to ITA° with an expected cumulative dose of approximately 100 to 250 mJ/cm² for the treated areas. For each subject the cumulative UVA and UVB doses will be recorded using a radiometer.

Participants will be assessed for clinical erythema 24 h (at 20 ±4 h) after exposure, clinical delayed pigmentation 1 week (on day 8 ±1 days) after exposure, and colorimetry performed at both 24 h and 1 week.

Intervention Type

Other

Primary outcome measure

Photoprotective effect measured using an erythema grading scale (grades 0-5) for all investigational areas assessed by a trained evaluator at 24 h

Secondary outcome measures

1. Skin redness measured using a Chromameter CR-400 (Konica Minolta) to record L* (lightness), a* (redness), and ITA° (overall colour) for all investigational areas at baseline, 24 h, and 1 week
2. Skin lightness measured using a Chromameter CR-400 (Konica Minolta) to record L*, a*, and ITA° for all investigational areas at baseline, 24 h and 1 week
3. Evolution of the pigmentation compared to negative control measured using a pigmentation grading scale (grades 0-4) for all investigational areas assessed by a trained evaluator at 1 week
4. Safety and tolerance measured using incidence of adverse events recorded between baseline and 1 week

Overall study start date

23/09/2021

Completion date

31/12/2021

Eligibility

Key inclusion criteria

1. Healthy subjects
2. Caucasian with Individual Typology Angle (ITA) ≥ 28°
2. Aged ≥18 and ≤55 years
3. Uniform skin color of the whole investigational area

Participant type(s)

Healthy volunteer

Age group

Adult

Lower age limit

18 Years

Upper age limit

55 Years

Sex

Both

Target number of participants

65

Total final enrolment

65

Key exclusion criteria

1. Pregnant or breastfeeding
2. Have used a sunbed or have had intensive sun exposure to the investigational areas within the 3 months before inclusion
3. ITA <28°
4. Tanned or sunburned (erythema) back
5. Dermatological disorders affecting the investigational areas (e.g. presence of multiple nevi, freckles, excess hair or uneven skin tones, tattoo, vitiligo, photo-dermatological disorders)
7. History of abnormal response to sun
8. History of allergy, hypersensitivity, or any serious reaction to any cosmetic product
9. Any concomitant medical condition that the investigator judges may interfere with the study

Date of first enrolment

01/11/2021

Date of final enrolment

08/12/2021

Locations

Countries of recruitment

Mauritius

Study participating centre

CIDP Lyee

Biopark, Socota Phoenicia

Sayed Hoseen Road

Phoenix

Mauritius

73408

Sponsor information

Organisation

Isdin (Spain)

Sponsor details

ISDIN

Provençals 33

Barcelona

Spain

08019

+34 932 402 020

scientificconsult@isdin.com

Sponsor type

Industry

Website

www.isdin.com

ROR

<https://ror.org/04dg86p75>

Funder(s)**Funder type**

Industry

Funder Name

ISDIN

Results and Publications**Publication and dissemination plan**

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

29/07/2022

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Mr Javier Bustos (Javier.bustos@isdin.com). Individual participant data (in the form of text, tables, figures, and appendices) that underlie the results reported in this article, after deidentification, will be available upon request after publication and ending 36 months after publication. The data sets are stored on spreadsheets and all appropriate requests for appropriate analysis and mechanisms will be considered.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		29/09/2022	30/09/2022	Yes	No